Ocular Therapeutix Inc (OCUL)
4.20
-0.44
(-9.58%)
USD |
NASDAQ |
Apr 25, 16:00
4.20
0.00 (0.00%)
After-Hours: 20:00
Ocular Therapeutix Enterprise Value: 569.49M for April 24, 2024
Enterprise Value Chart
Historical Enterprise Value Data
Date | Value |
---|---|
April 24, 2024 | 569.49M |
April 23, 2024 | 622.26M |
April 22, 2024 | 633.40M |
April 19, 2024 | 654.95M |
April 18, 2024 | 750.07M |
April 17, 2024 | 1.006B |
April 16, 2024 | 1.037B |
April 15, 2024 | 1.038B |
April 12, 2024 | 1.067B |
April 11, 2024 | 1.110B |
April 10, 2024 | 1.055B |
April 09, 2024 | 1.093B |
April 08, 2024 | 1.067B |
April 05, 2024 | 1.134B |
April 04, 2024 | 1.138B |
April 03, 2024 | 1.135B |
April 02, 2024 | 1.139B |
April 01, 2024 | 1.171B |
March 28, 2024 | 1.232B |
March 27, 2024 | 1.263B |
March 26, 2024 | 1.246B |
March 25, 2024 | 1.278B |
March 22, 2024 | 1.290B |
March 21, 2024 | 1.388B |
March 20, 2024 | 1.351B |
Date | Value |
---|---|
March 19, 2024 | 1.321B |
March 18, 2024 | 1.282B |
March 15, 2024 | 1.285B |
March 14, 2024 | 1.255B |
March 13, 2024 | 1.304B |
March 12, 2024 | 1.260B |
March 11, 2024 | 1.325B |
March 08, 2024 | 1.362B |
March 07, 2024 | 1.420B |
March 06, 2024 | 1.489B |
March 05, 2024 | 1.136B |
March 04, 2024 | 1.130B |
March 01, 2024 | 1.115B |
February 29, 2024 | 1.036B |
February 28, 2024 | 1.023B |
February 27, 2024 | 1.017B |
February 26, 2024 | 1.017B |
February 23, 2024 | 1.013B |
February 22, 2024 | 994.26M |
February 21, 2024 | 743.64M |
February 20, 2024 | 743.64M |
February 16, 2024 | 750.54M |
February 15, 2024 | 667.77M |
February 14, 2024 | 621.78M |
February 13, 2024 | 525.21M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
76.98M
Minimum
May 23 2019
1.663B
Maximum
Dec 22 2020
468.93M
Average
343.73M
Median
Enterprise Value Benchmarks
Assertio Holdings Inc | 46.99M |
CytomX Therapeutics Inc | -64.12M |
EyePoint Pharmaceuticals Inc | 489.66M |
Regeneron Pharmaceuticals Inc | 90.64B |
Cormedix Inc | 217.02M |
Enterprise Value Related Metrics
Net Income (Quarterly) | -29.22M |
Revenue (Quarterly) | 14.80M |
Total Expenses (Quarterly) | 34.85M |
EPS Diluted (Quarterly) | -0.35 |
Gross Profit Margin (Quarterly) | 90.64% |
Profit Margin (Quarterly) | -197.4% |
Earnings Yield | -29.76% |
Normalized Earnings Yield | -32.23 |